Pathogenetic traits of preeclampsia in COVID-19. A relevant literature review

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The aim of this study was to present the latest data on the association of preeclampsia and coronavirus infection and on the preeclampsia-like syndrome, and to analyze the current literature on the pathogenetic relationships between COVID-19 and preeclampsia and on morphological changes in placental tissue in patients with these gestational complications.

A significant portion of studies indicate an increased risk of developing preeclampsia in patients with coronavirus infection during pregnancy, regardless of gestational age, especially in severe COVID-19, but other researchers report no association between coronavirus infection and the onset of preeclampsia. The supposed pathogenetic connection between these pathologies consists in the development of systemic endothelial dysfunction and dysregulation of the renin-angiotensin-aldosterone system, while the direct effect of SARS-CoV-2 on the placentation is poorly understood and is a subject of debate. A new concept of the so-called “preeclampsia-like syndrome” has been introduced, which presumably occurs in patients with a severe form of the novel coronavirus infection as its extrapulmonary manifestation. The measurement of the ratio of soluble fms-like tyrosine kinase-1 activity to the level of placental growth factor ratio has been proposed as a differential diagnostic test between preeclampsia and the preeclampsia-like syndrome, but its prognostic value remains ambiguous. The morphological examination of placentas in patients with coronavirus infection and preeclampsia indicates the signs of maternal and fetal vascular malperfusion.

The literature on the association between coronavirus infection and preeclampsia remains controversial, however, the better half of the researchers is indicative of a significant increase in the risk of developing this serious complication in pregnant women with COVID-19, especially for its severe form. New information about the preeclampsia-like syndrome, as well as the virtual absence of studies of placental morphology in patients with preeclampsia and coronavirus infection during pregnancy, dictate the need for further study to better understand the association between these two pathologies, determine the possibilities of patient surveillance and prevent complications.

Full Text

Restricted Access

About the authors

Kseniia A. Rudenko

Almazov National Medical Research Centre

Author for correspondence.
Email: rudenko_ka@almazovcentre.ru
ORCID iD: 0000-0001-8498-7938

MD

Russian Federation, Saint Petersburg

Valentina V. Ishkaraeva

Almazov National Medical Research Centre

Email: ishkaraeva_vv@almazovcentre.ru
ORCID iD: 0000-0002-5391-7600

MD, Cand. Sci. (Med.)

Russian Federation, Saint Petersburg

Irina E. Zazerskaya

Almazov National Medical Research Centre

Email: zazera@mail.ru
ORCID iD: 0000-0003-4431-3917

MD, Dr. Sci. (Med.), Professor

Russian Federation, Saint Petersburg

References

  1. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). In: Johns Hopkins University. Coronavirus resource center [Internet]. Available from: https://coronavirus.jhu.edu/map.html
  2. Glynn SM, Yang YJ, Thomas C, et al. SARS-CoV-2 and placental pathology: malperfusion patterns are dependent on timing of infection during pregnancy. Am J Surg Pathol. 2022;46(1):51–57. doi: 10.1097/PAS.0000000000001772
  3. Jaiswal N, Puri M, Agarwal K, et al. COVID-19 as an independent risk factor for subclinical placental dysfunction. Eur J Obstet Gynecol Reprod Biol. 2021;259:7–11. doi: 10.1016/j.ejogrb.2021.01.049
  4. Overton EE, Goffman D, Friedman AM. The epidemiology of COVID-19 in pregnancy. Clin Obstet Gynecol. 2022;65(1):110–122. doi: 10.1097/GRF.0000000000000674
  5. Wang H, Li N, Sun C, et al. The association between pregnancy and COVID-19: a systematic review and meta-analysis. Am J Emerg Med. 2022;56:188–195. doi: 10.1016/j.ajem.2022.03.060
  6. Chief freelance obstetrics specialist of the Russian Ministry of Health Roman Shmakov: vaccination against COVID-19 during pregnancy and breastfeeding is necessary. In: Ministry of Health of the Russian Federation [Internet]. Available from: https://minzdrav.gov.ru/news/2021/12/02/17917-glavnyy-vneshtatnyy-spetsialist-po-akusherstvu-minzdrava-rossii-roman-shmakov-vaktsinatsiya-ot-covid-19-v-period-beremennosti-i-vo-vremya-grudnogo-vskarmlivaniya-neobhodima (In Russ.)
  7. Chmielewska B, Barratt I, Townsend R, et al. Effects of the COVID-19 pandemic on maternal and perinatal outcomes: a systematic review and meta-analysis. Lancet Glob Health. 2021;9(6):e759–e772. doi: 10.1016/S2214-109X(21)00079-6
  8. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ. 2021;193(16):E540–E548. doi: 10.1503/cmaj.202604
  9. Villar J, Ariff S, Gunier RB, et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study. JAMA Pediatr. 2021;175(8):817–826. doi: 10.1001/jamapediatrics.2021.1050
  10. Papageorghiou AT, Deruelle P, Gunier RB, et al. Preeclampsia and COVID-19: results from the INTERCOVID prospective longitudinal study. Am J Obstet Gynecol. 2021;225(3):289.e1–289.e17. doi: 10.1016/j.ajog.2021.05.014
  11. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022;226(1):68–89.e3. doi: 10.1016/j.ajog.2021.07.009
  12. Rao MG, Toner LE, Stone J, et al. Pregnancy during a pandemic: a cohort study comparing adverse outcomes during and before the COVID-19 pandemic. Am J Perinatol. 2023;40(4):445–452. doi: 10.1055/a-1877-5973
  13. Cardona-Pérez JA, Villegas-Mota I, Helguera-Repetto AC, et al. Prevalence, clinical features, and outcomes of SARS-CoV-2 infection in pregnant women with or without mild/moderate symptoms: Results from universal screening in a tertiary care center in Mexico City, Mexico. PLoS One. 2021;16(4). doi: 10.1371/journal.pone.0249584
  14. Lai J, Romero R, Tarca AL, et al. SARS-CoV-2 and the subsequent development of preeclampsia and preterm birth: evidence of a dose-response relationship supporting causality. Am J Obstet Gynecol. 2021;225(6):689–693.e1. doi: 10.1016/j.ajog.2021.08.020
  15. Mira AR, De Pinho A, Calado-Araújo M, et al. COVID-19 and hypertensive disorders of pregnancy (HDP): a portuguese multicentric retrospective cohort study of HDP in SARS-CoV-2 infected patients. Cureus. 2023;15(3). doi: 10.7759/cureus.36483
  16. Guida JP, Cecatti JG, Souza RT, et al. Preeclampsia among women with COVID-19 during pregnancy and its impact on maternal and perinatal outcomes: results from a national multicenter study on COVID in Brazil, the REBRACO initiative. Pregnancy Hypertens. 2022;28:168–173. doi: 10.1016/j.preghy.2022.05.005
  17. Adhikari EH, Moreno W, Zofkie AC, et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. JAMA Netw Open. 2020;3(11). doi: 10.1001/jamanetworkopen.2020.29256
  18. Pirjani R, Hosseini R, Soori T, et al. Maternal and neonatal outcomes in COVID-19 infected pregnancies: a prospective cohort study. J Travel Med. 2020;27(7). doi: 10.1093/jtm/taaa158
  19. Aydın GA, Ünal S, Özsoy HGT. The effect of gestational age at the time of diagnosis on adverse pregnancy outcomes in women with COVID-19. J Obstet Gynaecol Res. 2021;47(12):4232–4240. doi: 10.1111/jog.15051
  20. Metz TD, Clifton RG, Hughes BL, et al. Disease severity and perinatal outcomes of pregnant patients with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2021;137(4):571–580. doi: 10.1097/AOG.0000000000004339
  21. Litman EA, Yin Y, Nelson SJ, et al. Adverse perinatal outcomes in a large United States birth cohort during the COVID-19 pandemic. Am J Obstet Gynecol MFM. 2022;4(3). doi: 10.1016/j.ajogmf.2022.100577
  22. Epelboin S, Labrosse J, De Mouzon J, et al. Obstetrical outcomes and maternal morbidities associated with COVID-19 in pregnant women in France: a national retrospective cohort study. PLoS Med. 2021;18(11). doi: 10.1371/journal.pmed.1003857
  23. Mahajan NN, Kesarwani S, Kumbhar P, et al. Increased risk of early-onset preeclampsia in pregnant women with COVID-19. Hypertens Pregnancy. 2023;42(1). doi: 10.1080/10641955.2023.2187630
  24. Ives CW, Sinkey R, Rajapreyar I, et al. Preeclampsia-pathophysiology and clinical presentations: jacc state-of-the-art review. J Am Coll Cardiol. 2020;76(14):1690–1702. doi: 10.1016/j.jacc.2020.08.014
  25. Abramova MY, Churnosov MI. Modern concepts of etiology, pathogenesis and risk factors for preeclampsia. Journal of Obstetrics and Women’s Diseases. 2021;70(5):105–116. EDN: MITKYY doi: 10.17816/JOWD77046
  26. Karumanchi SA, Lim KL, August P. Preeclampsia: pathogenesis. In: UpToDate [Internet]. 2023. Available from: https://www.uptodate.com/contents/preeclampsia-pathogenesis
  27. Vasileva MY, Smirnov IV, Ishkaraeva VV, et al. Prognostic value of anti- and proangiogenic factors in severe preeclampsia. Journal of Obstetrics and Women’s Diseases. 2023;72(2):5–17. EDN: DJJUXG doi: 10.17816/JOWD159396
  28. Malik A, Jee B, Gupta SK. Preeclampsia: disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens. 2019;15:23–31. doi: 10.1016/j.preghy.2018.10.011
  29. Gammill HS, Chettier R, Brewer A, et al. Cardiomyopathy and preeclampsia. Circulation. 2018;138(21):2359–2366. doi: 10.1161/CIRCULATIONAHA.117.031527
  30. Tossetta G, Fantone S, Delli Muti N, et al. Preeclampsia and severe acute respiratory syndrome coronavirus 2 infection: a systematic review. J Hypertens. 2022;40(9):1629–1638. doi: 10.1097/HJH.0000000000003213
  31. Celewicz A, Celewicz M, Michalczyk M, et al. SARS CoV-2 infection as a risk factor of preeclampsia and pre-term birth. An interplay between viral infection, pregnancy-specific immune shift and endothelial dysfunction may lead to negative pregnancy outcomes. Ann Med. 2023;55(1). doi: 10.1080/07853890.2023.2197289
  32. Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 Infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913.e7. doi: 10.1016/j.cell.2020.04.004
  33. Lu-Culligan A, Chavan AR, Vijayakumar P, et al. Maternal respiratory SARS-CoV-2 infection in pregnancy is associated with a robust inflammatory response at the maternal-fetal interface. Med. 2021;2(5):591–610.e10. doi: 10.1016/j.medj.2021.04.016
  34. Sayad B, Mohseni Afshar Z, Mansouri F, et al. Pregnancy, preeclampsia, and COVID-19: susceptibility and mechanisms: a review study. Int J Fertil Steril. 2022;16(2):64–69. doi: 10.22074/IJFS.2022.539768.1194
  35. Giardini V, Ornaghi S, Gambacorti-Passerini C, et al. Imbalanced angiogenesis in pregnancies complicated by SARS-CoV-2 infection. Viruses. 2022;14(10):2207. doi: 10.3390/v14102207
  36. Sathiya R, Rajendran J, Sumathi S. COVID-19 and Preeclampsia: overlapping features in pregnancy. Rambam Maimonides Med J. 2022;13(1). doi: 10.5041/RMMJ.10464
  37. Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ Res. 2020;126(10):1456–1474. doi: 10.1161/CIRCRESAHA.120.317015
  38. Kosinska-Kaczynska K, Malicka E, Szymusik I, et al. The sFlt-1/PlGF ratio in pregnant patients affected by COVID-19. J Clin Med. 2023;12(3):1059. doi: 10.3390/jcm12031059
  39. Bloise E, Zhang J, Nakpu J, et al. Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia. Am J Obstet Gynecol. 2021;224(3):298.e1–298.e8. doi: 10.1016/j.ajog.2020.08.055
  40. Sertel E, Demir M. Evaluation of the effects of COVID-19 disease and the trimester in which the disease is diagnosed on obstetric and neonatal outcomes: a retrospective cohort study. J Obstet Gynaecol Res. 2023;49(2):614–624. doi: 10.1111/jog.15510
  41. Seethy AA, Singh S, Mukherjee I, et al. Potential SARS-CoV-2 interactions with proteins involved in trophoblast functions – an in-silico study. Placenta. 2021;103:141–151. doi: 10.1016/j.placenta.2020.10.027
  42. Beys-da-Silva WO, da Rosa RL, Santi L, et al. The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection. Biochim Biophys Acta Mol Basis Dis. 2021;1867(3). doi: 10.1016/j.bbadis.2020.165999
  43. Wong YP, Khong TY, Tan GC. The Effects of COVID-19 on placenta and pregnancy: what do we know so far? Diagnostics (Basel). 2021;11(1):94. doi: 10.3390/diagnostics11010094
  44. Motwani R, Deshmukh V, Kumar A, et al. Pathological involvement of placenta in COVID-19: a systematic review. Infez Med. 2022;30(2):157–167. doi: 10.53854/liim-3002-1
  45. Sharps MC, Hayes DJL, Lee S, et al. A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection. Placenta. 2020;101:13–29. doi: 10.1016/j.placenta.2020.08.018
  46. Di Girolamo R, Khalil A, Alameddine S, et al. Placental histopathology after SARS-CoV-2 infection in pregnancy: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2021;3(6). doi: 10.1016/j.ajogmf.2021.100468
  47. Patberg ET, Adams T, Rekawek P, et al. Coronavirus disease 2019 infection and placental histopathology in women delivering at term. Am J Obstet Gynecol. 2021;224(4):382.e1–382.e18. doi: 10.1016/j.ajog.2020.10.020
  48. Shchegolev AI, Tumanova UN, Serov VN. Placental lesions in pregnant women with SARS CoV-2 infection. Obstetrics and Gynecology. 2020;(12):44–52. EDN: KFUUWS doi: 10.18565/aig.2020.12.44-52
  49. Shchegolev AI, Kulikova GV, Tumanova UN, et al. Morphometric parameters of placental villi in parturient women with COVID-19. Bulletin of Experimental Biology and Medicine. 2021;172(1):85–89. EDN: VKSCTT doi: 10.47056/0365-9615-2021-172-7-102-107
  50. Boyraz B, James K, Hornick JL, et al. Placental pathology from COVID-19-recovered (nonacute) patients. Hum Pathol. 2022;125:18–22. doi: 10.1016/j.humpath.2022.04.005
  51. Garg R, Agarwal R, Yadav D, et al. Histopathological changes in placenta of severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and maternal and perinatal outcome in COVID-19. J Obstet Gynaecol India. 2023;73(1):44–50. doi: 10.1007/s13224-022-01666-3
  52. Bachnas MA, Putri AO, Rahmi E, et al. Placental damage comparison between preeclampsia with COVID-19, COVID-19, and preeclampsia: analysis of caspase-3, caspase-1, and TNF-alpha expression. AJOG Glob Rep. 2023;3(3). doi: 10.1016/j.xagr.2023.100234
  53. Naeh A, Berezowsky A, Yudin MH, et al. Preeclampsia-like syndrome in a pregnant patient with coronavirus disease 2019 (COVID-19). J Obstet Gynaecol Can. 2022;44(2):193–195. doi: 10.1016/j.jogc.2021.09.015
  54. Mendoza M, Garcia-Ruiz I, Maiz N, et al. Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study. BJOG. 2020;127(11):1374–1380. doi: 10.1111/1471-0528.16339
  55. Serrano B, Bonacina E, Garcia-Ruiz I, et al. Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study. Am J Obstet Gynecol MFM. 2023;5(1). doi: 10.1016/j.ajogmf.2022.100760
  56. Taglauer ES, Wachman EM, Juttukonda L, et al. Acute severe acute respiratory syndrome coronavirus 2 infection in pregnancy is associated with placental angiotensin-converting enzyme 2 shedding. Am J Pathol. 2022;192(4):595–603. doi: 10.1016/j.ajpath.2021.12.011
  57. Nobrega GM, Guida JP, Novaes JM, et al. Role of biomarkers (sFlt-1/PlGF) in cases of COVID-19 for distinguishing preeclampsia and guiding clinical management. Pregnancy Hypertens. 2023;31:32–37. doi: 10.1016/j.preghy.2022.11.008
  58. Kwiatkowski S, Borowski D, Kajdy A, et al. Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic. Ultrasound Obstet Gynecol. 2020;55(6):841–843. doi: 10.1002/uog.22049

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eсо-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies